lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed and are posted here as part of a 12-month trial. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

Development and Validation a Prognostic Nomogram for Hepatocellular Carcinoma Patients Incorporating with Microvascular Invasion and Hematological Biomarkers

23 Pages Posted: 29 Mar 2019

See all articles by Xiufen Li

Xiufen Li

Sun Yat-Sen University (SYSU) - Cancer Center

Hao Huang

Sun Yat-Sen University (SYSU) - Department of Laboratory Medicine

Xuegao Yu

Third People’s Hospital of Shenzhen

Xiaomin Liu

Sun Yat-Sen University (SYSU)

Xin Zheng

Sun Yat-Sen University (SYSU)

Bin Huang

Sun Yat-Sen University (SYSU)

More...

Abstract

Background: This study aimed to develop and validate a nomogram for overall survival (OS) prediction in which combine clinical characteristics and hematological biomarkers in patients with hepatocellular carcinoma (HCC).   

Method: We performed a retrospective analysis of 807 HCC patients. All the clinical data of these patients were collected through electronic medical record(EMR). The independent predictive variables were identified by cox regression analysis. We tested the accuracy of the nomograms by discrimination and calibration, and then plotted decision curves to assess the benefits of nomogram-assisted decisions in a clinical context, and compared with the TNM staging systems and MVI on HCC prognosis.    

Findings: The primary cohort consisted of 545 patients with clinicopathologically diagnosed with HCC from 2008 to 2013, while 262 patients from 2014 to 2016 in external validation cohort. Variables included in the nomograms were TNM Stage, microvascular invasion (MVI), alpha fetoprotein (AFP), platelet to lymphocyte ratio(PLR) and prothrombin time (PT). The C-index of nomogram was 0.768, which was superior than the C-index of TNM Stage(0.660, P<0.001) and MVI(0.664, P<0.001) alone in the primary cohort. In the validation cohort, the models had a C-index of 0.845, and were also statistically higher when compared to C-index values for TNM Stage(0.687, P<0.001) and MVI(0.684, P<0.001). Calibration curves showed adequate calibration  of predicted and reported OS prediction throughout the range of HCC outcomes. Decision curve analysis demonstrated that the nomogram was clinically useful than the TNM Stage and MVI alone. Moreover, patients were divided into three distinct risk groups for OS by the nomogram: low risk group, middle risk group and a high risk group, respectively.    

Interpretation: The nomogram presents more accurate and useful prognostic power, which could be used to predict OS for patients with HCC.   

Funding Statement: The authors stated: "No specific funding was disclosed."

Declaration of Interests: The authors have declared that they have no conflict of interest.

Ethics Approval Statement: The study was approved by the ethics committees in The First Affiliated Hospital of Sun Yat-sen University (Guangdong, China).

Keywords: Nomogram, Hepatocellular carcinoma , Prognosis, Microvascular invasion, Hematological biomarker

Suggested Citation

Li, Xiufen and Huang, Hao and Yu, Xuegao and Liu, Xiaomin and Zheng, Xin and Huang, Bin, Development and Validation a Prognostic Nomogram for Hepatocellular Carcinoma Patients Incorporating with Microvascular Invasion and Hematological Biomarkers (March 27, 2019). Available at SSRN: https://ssrn.com/abstract=3361156

Xiufen Li

Sun Yat-Sen University (SYSU) - Cancer Center ( email )

651 Dongfeng East Road
Guangzhou, 510060
China

Hao Huang (Contact Author)

Sun Yat-Sen University (SYSU) - Department of Laboratory Medicine ( email )

Guangzhou, 510080
China

Xuegao Yu

Third People’s Hospital of Shenzhen

Shenzhen
China

Xiaomin Liu

Sun Yat-Sen University (SYSU)

135, Xingang Xi Road
Guangzhou, Guangdong 510275
China

Xin Zheng

Sun Yat-Sen University (SYSU)

135, Xingang Xi Road
Guangzhou, Guangdong 510275
China

Bin Huang

Sun Yat-Sen University (SYSU)

135, Xingang Xi Road
Guangzhou, Guangdong 510275
China

Click here to go to TheLancet.com

Go to TheLancet.com

Paper statistics

Abstract Views
10
Downloads
2